ArticleHaematologica2025
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study.
Arthur Bobin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papertrialcites it